期刊文献+

miR-196a靶向调控HOXA9基因的实验研究 被引量:2

HOXA9 is direct target of miR-196a
下载PDF
导出
摘要 目的:研究HOXA9基因的表观遗传学调控机制,筛选靶向调控HOXA9基因的microRNA。方法:利用Tar-getscan在线分析软件预测特异性靶向HOXA9基因3'端非编码区域(3’UTR)的microRNA,采用PCR方法从1例健康供者DNA中扩增HOXA9基因3’UTR序列,插入经XbaI和PstI双酶切的荧光素酶报告载体pGL3-M,采用脂质体SuperFect包裹荧光素酶重组质粒及microRNA表达质粒转染293T细胞,应用双荧光素酶检测试剂盒测定荧光素酶活性。构建miR-196a结合位点突变的HOXA9基因3’端非编码区域突变型荧光素酶报告载体,采用脂质体SuperFect包裹荧光素酶突变型重组质粒及miR-196a表达质粒转染293T细胞,应用双荧光素酶检测试剂盒测定荧光素酶活性。miR-196amimics以脂质体Hiperfect转染至MV4-11细胞,实时定量PCR及Westernblot检测HOXA9mRNA及蛋白的表达。结果:成功构建了含有1628bp的HOXA9基因3’UTR序列的荧光素酶报告重组质粒pGL3-HOXA9-3’UTR,并通过酶切及基因测序方法的鉴定;荧光素酶报告实验提示miR-196a组荧光素酶活性明显低于对照组。成功构建了miR-196a的2个结合位点突变的HOXA9基因3’UTR序列的突变型荧光素酶报告重组质粒pGL3-HOXA9-mut3’UTR,并通过基因测序方法的鉴定。miR-196a可以下调野生型质粒的荧光素酶活性,不影响突变型质粒的荧光素酶活性。MV4-11细胞中过表达miR-196a,可以明显下调HOXA9mRNA及蛋白表达。结论:miR-196a通过靶向结合HOXA9基因3’UTR的结合位点特异调控HOXA9基因。 AIM: To analyze the possible epigenetic regulation mechanism of HOXA9 gene expression and find the possible microRNA regulating HOXA9 gene expression. METHODS: Targetscan software was used to analyze potential microRNA target sites in 3 '-UTR of human HOXAg. 3'-UTR fragment of HOXA9 was amplified by PCR. PCR products were cloned into Xba I/Pst I-digested pGL3-M reporter vector, placing the 3'-UTR with potential microRNA binding sites downstream of coding sequence of luciferase. Mutant 3'UTRs were generated by overlap extension PCR method. The construct was cotransfected in 293T cells with control plasmid or plasmids expressing microRNAs regula- ting HOXA9 potentially. Western blot and RT-PCR were used to detect the expression level of HOXA9 protein and mRNA in MV4-11 cells after transfection of miR196a. RESULTS: The results of luciferase assays revealed that overexpression of miR-196a could reduce the luciferase activity from the reporter construct containing the HOXA9 3 '-UTR significantly. The activity of the reporter construct mutated at the specific miR-196a target site was unaffected. Protein and mRNA of HOXA9 was found to be downregulated by miR-196a. CONCLUSION: Theses results suggested that miR-196a regulates the expression of HOXA9 by targeting the complementary sites.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2011年第2期166-169,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目(30800482 90919044) 国家重点基础研究发展计划(973)资助项目(2005CB522400) 首都医学发展科研基金资助项目(2007-2040)
关键词 MICRORNA 白血病 HOXA9基因 荧光素酶报告实验 microRNA leukemia HOXA9 gene luciferase assays
  • 相关文献

参考文献8

  • 1Whelan JT,Ludwig DL,Bertrand FE.HoxA9 induces insμLin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia[J].Leukemia,2008,22(6):1161-1169.
  • 2Erfurth FE,Popovic R,Grembecka J,et al.MLL protects cpG clusters from methylation within the Hoxa9 geue,maintaining transcript expression[J].Proc Natl Acad Sci USA,2008,105(21):7517-7522.
  • 3Faber J,Krivtsov AV,Stubbs MC,et al.HOXA9 is required for surrival in human MLL-rearranged acute leukemias[J].Blood,2009,113(11):2375-2385.
  • 4Faber J,Krivtsov AV,Stubbs MC,et al.MicroRNA-126 regμLates HOXA9 by binding to the homeobox[J].Mol Cell Biol,2008,28(14):4609-4619.
  • 5Marcucci G,Mrózek K,Radmacher MD,et al.MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias[J].Best Pract Res Chn Haematol,2009,22(2):239-2348.
  • 6Ritchie WJ,Flamant S,Rasko JE.MicroRNA in acute myeloid leukemia[J].N Engl J Med,2008,359(6):653.
  • 7Ju X,Li D,Shi Q,et al.Differential micreRNA expression in childhood B-cell precursor acute lymphoblastic leukemia[J].Pediatr Hematel Oncel,2009,26(1):1-10.
  • 8Liu Q.Fu H,Sun F,et al.miR-16 family induces cell cycle arrest by regμLating mμLtiple cell cycle genes[J].Nucleic Acids Res,2008,36(16):5391-5404.

同被引文献19

  • 1王莉红,周春林,张新伟,陈森,王敏,王建祥.FLT3基因内部串联重复突变与急性白血病的关系及临床意义[J].中华血液学杂志,2004,25(7):393-396. 被引量:35
  • 2Dohner H,Gaidzik VI. Impact of genetic features on treatment decisions in AML[J].Hematol Am Soc Hematol Educ Program,2011.36-42.
  • 3Marcucci G,Haferlach T,Dohner H. Molecular genetics of adult acute myeloid leukemia:Prognostic and therapeutic implications[J].Journal of Clinical Oncology,2011,(05):475-486.
  • 4Zhang W,Konopleva M,Shi YX. Mutant FLT3:A direct target of sorafenib in acute myelogenous leukemia[J].JOURNAL OF THE NATIONAL CANCER INSTITUTE,2008,(03):184-198.
  • 5Sumi D,Shinkai Y,Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells[J].Toxicology and Applied Pharmacology,2010,(03):385-392.
  • 6Dou L,Zheng D,Li J. Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression[J].Oneogene,2012,(04):507-517.
  • 7Kottaridis PD,Gale RE,Frew ME. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy:Analysis of 854 patients from the united kingdom medical research council AML 10 and 12 trials[J].Blood,2001,(06):1752-1759.
  • 8Meshinchi S,Woods WG,Stirewalt DL. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia[J].Blood,2001,(01):89-94.
  • 9Pratz KW,Levis MJ. Bench to bedside targeting of FLT3 in acute leukemia[J].Current Drug Targets,2010,(07):781-789.
  • 10Pratz KW,Sato T,Murphy KM. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML[J].Blood,2010,(07):1425-1432.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部